local_hospital

University Hospital Jena KöR

Address
lock Available on a paid plan

Oncology and Hematology

At University Hospital Jena KöR, a major share of research focuses on oncology and hematology, with studies spanning blood cancers, solid tumors, and transplant-related care. The trials aim to improve treatment effectiveness, refine risk-adapted care, and test new therapeutic combinations for difficult-to-treat diseases.

  • Acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes
  • Diffuse large B-cell lymphoma, Hodgkin lymphoma, and other lymphomas
  • Breast cancer, lung cancer, urothelial cancer, and renal cell carcinoma
  • Head and neck cancer, prostate cancer, and ovarian cancer

Research here often explores whether newer treatment strategies can improve survival, deepen remission, or support patients before and after stem cell transplantation.

Immunology, Autoimmune Disease, and Inflammation

The site also conducts clinical trials in immune-mediated and autoimmune diseases, aiming to better control chronic inflammation and reduce disease flares. These studies are designed to evaluate treatment benefit, safety, and long-term disease control in conditions that can strongly affect daily life.

  • Crohn’s disease and ulcerative colitis
  • Systemic lupus erythematosus, lupus nephritis, and systemic sclerosis
  • Rheumatoid arthritis, myasthenia gravis, and immune thrombocytopenia
  • Myelofibrosis and other inflammatory hematologic disorders

Several projects aim to improve symptom control and identify better ways to match patients with the most effective immunomodulatory therapies.

Neurology and Neuroscience

Clinical research in neurology at the University Hospital Jena KöR covers both neurodegenerative and inflammatory conditions, with a strong emphasis on improving function, slowing progression, and easing symptoms. The trials examine new treatment options and better ways to measure neurological outcomes.

  • Multiple sclerosis and secondary progressive multiple sclerosis
  • Amyotrophic lateral sclerosis
  • Epilepsy, including Dravet syndrome and generalized seizure disorders
  • Alzheimer’s disease and other cognitive disorders

This portfolio reflects a broad effort to test therapies that may preserve neurological function, improve quality of life, and support earlier intervention in progressive disease.

Cardiovascular and Renal Medicine

Another important research area combines cardiovascular disease and kidney disease, with trials focused on prevention, complication reduction, and better long-term outcomes. These studies often address patients with overlapping heart, vascular, and renal conditions.

  • Heart failure, atrial fibrillation, and myocardial infarction
  • Atherosclerotic cardiovascular disease and hypercholesterolemia
  • Chronic kidney disease, acute kidney injury, and IgA nephropathy
  • Hypertrophic cardiomyopathy and cardiorenal complications

The research includes evaluation of new approaches to reduce hospitalization, protect kidney function, and improve management of high-risk cardiovascular patients.

Respiratory, ENT, and Infectious Disease Research

The hospital’s ear, nose, and throat department contributes to trials in otorhinolaryngologic diseases, while related studies also address respiratory and infectious conditions. The research aims to improve diagnosis, symptom relief, and treatment effectiveness across common and complex disorders.

  • Chronic rhinosinusitis and nasal polyps
  • Sensorineural hearing loss
  • Asthma, bronchiectasis, and cystic fibrosis
  • Staphylococcus aureus bacteremia, sepsis, and other serious infections

These studies reflect a strong interest in improving care for patients with chronic airway disease, hearing disorders, and infection-related complications.

Gastroenterology, Liver Disease, and Transplantation

Research in gastroenterology and hepatology includes inflammatory bowel disease, liver failure, and transplant-related conditions. The trials are designed to test better treatments, support recovery, and improve outcomes in patients with advanced digestive and liver disorders.

  • Crohn’s disease and ulcerative colitis
  • Acute-on-chronic liver failure, cirrhosis, and hepatorenal syndrome
  • Liver transplantation and graft-versus-host disease
  • Gastrectomy-related recovery and esophagogastric cancer

Several studies focus on improving digestive disease management, supporting transplant patients, and evaluating strategies that may enhance quality of life after major surgery.

Pediatric and Rare Disease Research

The site also participates in trials for children and adolescents with rare and complex diseases, including cancers, genetic disorders, and immune conditions. These studies aim to improve survival, reduce treatment burden, and support more personalized care.

  • Neuroblastoma, Ewing sarcoma, and atypical teratoid/rhabdoid tumor
  • Pediatric leukemia and pediatric lymphoma
  • Congenital and hereditary disorders such as FNAIT
  • Cystic fibrosis and other rare chronic diseases

This research highlights a commitment to advancing care for younger patients with high-need rare conditions, where new treatment options can make a major difference.

Site Overview

assignment
321
connected trials
corporate_fare
147
sponsors
science
500
IMPs

Activity Indicator

Last 6 months

28
Trials started
-32% vs previous period.
41
Trials started 6–12 months ago
321
Total trials linked
Highly Active
trending_downDeclining-32%
5
5
8
5
4
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 23 therapeutic areas and 15 of 500 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 459 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
176
Sponsors (total)
147
Active sponsors
95

Sponsor Network

Top 95 by active trials.

lock +94 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +51 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
321
Outperforms 99% of sites
public
Therapeutic diversity
25areas
Outperforms 99% of sites
groups
Sponsor diversity
147sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in University Hospital Jena KöR

lock Showing 1 of 321 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studiesBayer Consumer Care AGPhase IIINot RecruitingOct 2020

IMP list

lock Showing 1 of 500 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab24Unknown2017-06-082026-06-01

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.